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2324Preamble
The use of standardized language is essential for all
communication in medicine, with the ultimate goal of
improved patient care. This is the driving force for
enhanced use of clinical data and standardization of the
lexicon of cardiovascular medicine to enhance the use of
clinical data. The American College of Cardiology (ACC)/
American Heart Association (AHA) Task Force on
Clinical Data Standards (Task Force) is at the fulcrum of
these efforts, bringing together the 2 largest professional
organizations that represent the House of Cardiology.
The mission statements of the ACC (“to transform
cardiovascular care and improve heart health”) and the
AHA (“building healthier lives, free of cardiovascular
diseases and stroke”) have direct relevance to the work of
the Task Force. The harmonization of cardiovascular ter-
minology enables improved clinical communication, opti-
mizes quality assurance, enhances process improvement
efforts, facilitates clinical research, and is critical to the
development and analysis of registries. Therefore, the work
of the Task Force supports, enables, and advances the
organizations’ missions, visions, and strategies of key car-
diovascular organizations in improving cardiovascular
health.
This document is an update of the 2007 methodology
paper (1). The goals of the current publication are 1) to
describe recent changes in the methods for construction of
data elements, 2) to clarify the current policies of the ACC
and AHA regarding the relationships of Task Force and
writing group members with industry and other entities, 3)
to describe the need for harmonization of data across or-
ganizations and disciplines, 4) to articulate our position on
the stewardship of cardiovascular terminology and the data
concepts thereof, and 5) to describe our roles and ap-
proaches to accelerating the interoperability of cardiovas-
cular data across the clinical, research, industry, registry,
regulatory, administrative, and public domains.
The processes of data standard development and the
work of the Task Force are dynamic, changing to be in line
with the best available science and to facilitate optimal and
cost-effective care, as well as clinical research. These
changes are aimed at serving the members of the ACC,
AHA, other healthcare professionals, and regulatory
agencies and industry. Although many groups continue to
develop and deﬁne the cardiovascular lexicon, this Task
Force is committed to facilitating communication among
organizations and key stakeholders to promote uniformity
in cardiovascular terminology through the publication of
commissioned manuscripts or revision and subsequent
approval of previously developed documents. The
continued emphasis of the Task Force is to promote a
standardized terminology and encourage the usage of this
uniﬁed lexicon. This document outlines current goals and
methodology and proposes a road map for potentialexpansion of related activities to best serve all in the car-
diovascular community.
Robert C. Hendel, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Clinical Data Standards1.0. Introduction
The ACC and AHA support the goals of their members to
improve cardiovascular care and disease prevention through
professional education, promotion of research, develop-
ment of guidelines, and the formation of standards for
cardiovascular care. All of this is focused on optimizing
patient care and outcomes.
A common, standardized vocabulary of cardiovascular
data elements is essential for healthcare professionals to
communicate most effectively about clinical care, as well as
to conduct clinical research involving observational studies,
clinical trials, and data registries. Clinical documents,
including procedural reports and reports of patient en-
counters, must use a common language to facilitate
communication and incorporation of this information into
structured reports and electronic health records (EHRs).
Standardization of these records, especially with wide-
spread use of EHRs, enables sharing of consistent data
between providers. Additionally, clinical studies including
randomized trials and data registries may provide a wealth
of information, often composed of numerous data elements
collected on hundreds of thousands of patients worldwide.
Comparative analysis and interpretation of these studies
also requires the use of standardized data deﬁnitions.
Regulatory processes and healthcare operations, including
U.S. Food and Drug Administration (FDA) submissions,
compliance, and billing documentation can be greatly
simpliﬁed by the use of a common parlance.
The ACC and AHA recognize the importance of data
standards for describing the process and outcomes of
clinical care whether in randomized trials, observational
studies, registries, or quality improvement initiatives.
Furthermore, the ACC and AHA agree that this common
language must be instituted to further integrate the use of
EHRs. Broad professional agreement on a common vo-
cabulary with clear deﬁnitions will facilitate all of these
functions.
The development of quality performance measurement
initiatives, particularly those for which an evaluation of
providers is an implicit or explicit aim, has further raised
awareness among the professional community about the
importance of data standards. This includes the develop-
ment and use of performance measures and other quality
metrics. A wide audience, including nonmedical pro-
fessionals such as payers, regulators, and consumers, may
therefore draw conclusions about outcomes in care based
on these standards. For a fair comparison of care patterns
and outcomes, the data elements that make up the de-
scriptions of these patterns and outcomes must be clearly
JACC Vol. 63, No. 21, 2014 Hendel et al.
June 3, 2014:2323–34 ACC/AHA Data Standards Methodology
2325deﬁned, be consistently used, reﬂect current practice
guidelines and recommendations, and be properly inter-
preted by a broad audience.
2.0. The ACC/AHA Task Force on
Clinical Data Standards
2.1. History and Charge
To further efforts aimed at standardizing data and data
deﬁnitions, the Task Force was established in 2004. The
charge of this Task Force is to undertake the development
and publication of clinical data standards composed of data
elements and corresponding deﬁnitions to describe the
evaluation, treatment, and outcomes of patients. Reporting
to the ACC Board of Trustees and the AHA Science
Advisory and Coordinating Committee, this Task Force is
charged with serving as a source of expertise on clinical
data standards, with tasks involved in directing the devel-
opment and maintenance of data standards and deﬁnitions
for cardiovascular medicine. As such, the publication of a
set of clinical data standards represents the formal position
and ofﬁcial policy of both organizations. To achieve these
goals, the Task Force was charged with the following
speciﬁc tasks:
1. Specify areas in cardiovascular medicine where data
standards are required for research and epidemio-
logical assessments and for use in clinical registries
and cardiovascular disease–related documents such
as guidelines, appropriate use criteria, and perfor-
mance measures.
2. Specify and deﬁne, as appropriate, the data elements
and corresponding deﬁnitions to be used in
describing patient, diagnostic, and procedural char-
acteristics; clinical management; and outcomes.
3. Deﬁne the methodology to guide the development
and maintenance of clinical data standards.
4. Develop explicit strategies and processes to promote
ongoing harmonization of clinical data standards
across all ACC and AHA clinical documents and
initiatives and potentially with other organizations
and stakeholders.
5. Optimize opportunities for sharing data across
various sources to promote optimal cardiovascular
care and disease prevention.
6. Collaborate with other organizations and with in-
ternal ACC and AHA committees, including, but
not limited to, the ACC/AHA Task Force on
Performance Measures, the ACC/AHA Task Force
on Practice Guidelines, the National Cardiovascular
Data Registry, the Scientiﬁc and Quality Oversight
Committee, the AHA Get With The Guidelines
Steering Committee, the Guideline Advantage
Program of the AHA, the American Diabetes As-
sociation, and American Cancer Society, the AHAExecutive Database Steering Committee, and the
ACC Informatics and Health Information Tech-
nology Task Force, as appropriate, in the develop-
ment, maintenance, and promotion of clinical data
standards.
7. Identify strategies to promote and implement ACC/
AHA clinical data standards in a wide variety of
environments, including, but not limited to, EHRs.2.2. Relationship of the Task Force on
Clinical Data Standards With Other
Standards Organizations
The Task Force recognizes that data standardization ac-
tivities are performed by groups outside of this Task Force,
both within and outside the ACC and the AHA. The
Clinical Data Interchange Standards Consortium has been
spearheading the formation of data elements for clinical
trials and regulatory submissions. A recent initiative
cosponsored by the FDA and Duke Clinical Research
Institute, entitled the Standardized Data Collection for
Cardiovascular Imaging Initiative, has focused on devel-
oping cardiovascular data standards for documenting the
ﬁndings of imaging studies as needed for regulatory de-
cisions. Additionally, subgroups and additional projects
have been undertaken within the AHA and ACC,
including, but not limited to, registries from Get With
The Guidelines (2) and the National Cardiovascular Data
Registry (3), such as CathPCI, ACTION RegistryGet
With The Guidelines (AR-G), and Carotid Artery
Revascularization and Endarterectomy (CARE). Other
organizations, such as the Academic Research Consortium
(ARC) (4) and its Bleeding (BARC), Peripheral (PARC),
and Valve (VARC) work groups, have been involved in
data element construction. Unfortunately, many of these
initiatives operate independently without centralized pro-
cess or output.
Although groups such as Health Level Seven (HL7) (5),
Systematized Nomenclature of MedicinedClinical Terms
(SNOMED-CT), and Digital Imaging and Communi-
cations in Medicine (DICOM) emphasize data transport
and interoperability, the Task Force is charged with the
development, selection, and maintenance of clinical deﬁ-
nitions as data standards. Therefore, a central role is
envisioned for the Task Force in the creation and
harmonization of data elements fundamental to the work
of other groups focusing on accomplishing interoperability
and integration aspects.
2.3. ACC/AHA Stewardship of
Cardiovascular Data Standards
As the 2 largest and most broadly representative organi-
zations in cardiovascular medicine in the United States, the
ACC and AHA represent a broad coalition of pro-
fessionals. It is the position of these parent organizations
that the Task Force be responsible for the stewardship of
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Force is to work closely with other stakeholders, including
other subspecialty societies such as the Society of Thoracic
Surgeons, the Heart Rhythm Society, the Clinical Data
Interchange Standards Consortium, as well as the FDA, in
developing a uniform lexicon for cardiovascular medicine.
Over the past several years, the Task Force has demon-
strated its ability to convene multiple stakeholder groups to
develop andmaintain data standards for amultitude of needs,
including structured reporting, EHRs, clinical registries and
databases, and regulatory requirements. Given this back-
ground, it is the position of theACCandAHAthat theTask
Force should serve as the single coordinating body for all
cardiovascular data standard efforts and initiatives. When
new data sets are to be developed or speciﬁc data elements
require revision, the Task Force should coordinate these
activities, bringing relevant stakeholders, including non-
cardiology groups, into the process to reach consensus on a
single, harmonized set of cardiovascular data standards and
deﬁnitions. This clearinghouse approach will ultimately
alleviate the confusion that currently exists when multiple
groups develop data standards. Although the Task Force
recognizes that it does not and should not hold a monopoly
on the process of developing data standards, theTask Force is
ideally suited to optimize harmonization across many efforts
to develop and maintain a consistent cardiovascular lexicon.
Furthermore, the Task Force is committed to maintaining a
rigorous and transparent process, as detailed in this docu-
ment, preserving the integrity of the data standards produced
while reducing the impact of potential conﬂicts of interest. It
is through careful peer review and public comment that the
Task Force standards have their strength, as well as the fact
that the data standards documents reﬂect the ofﬁcial policy
statements of the ACC and AHA.
3.0. Document Development Processes
3.1. Selection of Topics
The Task Force selects potential topics for creation of
clinical data standards based on the importance of the car-
diovascular condition or procedure, as well as the needs of
the cardiovascular community. This may also include up-
dates or revisions of existing data standards created by the
Task Force in prior years. After topic selection, which is
discussed and approved by the entire Task Force, the actual
work product is created by a writing committee commis-
sioned by the Task Force. Ultimately, standards approved
ﬁrst by the Task Force and then by the ACC Board of
Trustees and the AHA Science Advisory and Coordinating
Committee are published jointly in their respective journals,
Journal of the American College of Cardiology and Circulation.
3.2. Composition of the Writing Committee
Once a topic has been selected, the Task Force names a
chair of the writing committee, who works with TaskForce members to select the members of the writing
committee. Nominations for this committee are solicited
from other key organizations and representatives from the
cardiovascular community. Relevant professional organi-
zations are invited to submit nominations to provide
expertise and knowledge in a particular discipline. From
the nominations received, the writing committee chair, in
consultation with the Task Force, selects representatives
from each invited professional organization. All partici-
pating organizations are given an opportunity to review the
ﬁnal document and are encouraged to endorse and/or
publish it in the participating organizations’ scientiﬁc
journals.
3.3. RelationshipsWith IndustryandOther Entities
The Task Force makes every effort to avoid actual,
potential, or perceived conﬂicts of interest that may arise as
a result of relationships with industry or other entities. All
members of the writing committee, as well as those
selected to serve as peer reviewers of the documents, are
required to disclose all current relationships and those
existing within the 12 months before initiation of the
writing effort. It is also required that the writing committee
chair and at least 50% of writing committee members have
no relevant relationships with industry and other entities
(RWI). Because clinical data standards documents do not
contain recommendations for clinical care or the use of
speciﬁc products, the potential to beneﬁt a speciﬁc phar-
maceutical or device manufacturer should be negligible.
Therefore, the Task Force has determined that only re-
lationships with for-proﬁt companies that maintain or li-
cense clinical vocabularies or clinical code sets or
companies that provide solutions or products related to the
application of data standards, such as EHR vendors, are
relevant to data standards documents. A formal policy to
this effect has been adopted by both the ACC and the
AHA. Any writing committee member who develops new
RWI during his or her tenure on the writing committee is
required to notify the data standards staff in writing. These
statements are reviewed periodically by the Task Force and
members of the writing committee. Author and peer
reviewer relationships with industry and other entities
relevant to the data standards document are also disclosed
in the document. For this document, relevant relationships
disclosed by writing committee members and peer re-
viewers are listed in Appendixes 1 and 2, respectively.
Additionally, to ensure complete transparency, writing
committee members’ comprehensive disclosure informa-
tion, including relationships not relevant to this data
standards document, is available online (see Comprehen-
sive RWI Table).
3.4. Consensus Development
The ACC/AHA data standards are intended to be
consensus, team-written documents. Each writing com-
mittee member contributes his or her expertise in
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Therefore, the ﬁnal document reﬂects the agreement of the
writing committee members in the creation of a formal,
recognized set of clinical data standards. The writing
committee usually meets both in person and by conference
call over the course of the development of a document.
Consensus is reached through discussion, e-mail, formal
surveys, and conﬁdential vote.
4.0. Building the Cardiovascular Vocabulary
4.1. Selection of Data Elements
Standard clinical concepts are evaluated to identify the
list of candidate data elements. To ensure consistency,
previously published versions of clinical data standards
that remain acceptable should be adopted whenever
possible. It is recognized that some terms are well estab-
lished and may not need further deﬁnition by the Task
Force. In the interest of harmonization, in many instances,
the Task Force or writing committee may simply adopt or
refer to terms from other documents or organizations such
as terminologies pertaining to demographic information,
symptoms, procedural details, laboratory test results, and
medical treatments unless there are compelling reasons not
to do so.
4.2. Data Element Components
Previous Task Force publications on data standards have
primarily included listings of the data elements and data
element deﬁnitions. To provide greater clarity, particularly
for users involved in data collection and data management,
the Task Force is expanding data element speciﬁcations to
include the following data ﬁelds: 1) data element, 2) data
element deﬁnition, 3) permissible values, 4) permissible
value deﬁnitions, and 5) source deﬁnitions; that is, the
source of the deﬁnition of a terminology, whether derived
from the published literature, controlled terminology
servers, registries, or other sources. The data element
“myocardial infarction,” its deﬁnition, and other speciﬁ-
cations (6) are shown in Appendix 3.
With the rapidly changing and evolving need for stan-
dardized medical nomenclature that can be used for health
information exchanges, the Task Force envisions the need to
also specify the data ﬁelds to include 1) permissible value
data type (statistical; e.g., categorical, Boolean, ordinal,
cardinal, nominal, date-time), 2) permissible value data
format (computational concepts; e.g., integer, whole num-
ber, yes-no, date-time, text), and 3) for dependent variables
(“daughter variable”), identiﬁcation of the parent and type of
dependency. The addition of these data ﬁelds may be per-
formed by other groups, such as the ACC Informatics and
Health Information Technology Task Force and external
organizations to more completely include the informatics
needed for effective computational use.4.3. Comprehensive Review of the
Literature and Relevant Sources
The Task Force supports gathering candidate data ele-
ments and deﬁnitions from as many relevant resources as
possible. Central to the foundation of all clinical data
standards is a comprehensive review of the published
literature and available resources. Examples of such re-
sources include
1. Previously published ACC/AHA data standards,
guidelines, and performance measures documents,
ACC appropriate use criteria documents (http://
www.cardiosource.org/Science-And-Quality/Practice-
Guidelines-and-Quality-Standards.aspx), and other
relevant national guidelines and clinical statements;
2. ACC/AHA registries, as well as other national and
international registries, such as the Society of
Thoracic Surgeons;
3. Intersocietal Accreditation Commission;
4. Cardiovascular subspecialty societies;
5. Standardized healthcare coding organizations and
projects, including the International Classiﬁcation
of Diseases, SNOMED-CT, DICOM, Logical
Observation Identiﬁers Names and Codes, and
RxNorm;
6. Government standardization initiatives, including
those from the FDA, Center for Medicare and
Medicaid Services, Department of Health and Hu-
man Services, Ofﬁce of the National Coordinator for
Health Information Technology, and the Centers
for Disease Control and Prevention;
7. Clinical trial documentation and source material;
8. Metrics related to performance measurements
derived from groups such as the National Quality
Forum and The Joint Commission.4.4. Development of Data Elements
and Deﬁnitions
The overriding goal in developing clinical data standards is
to focus on important variables needed to assess patient
characteristics, including risk factors, lifestyle, severity of
disease state, diagnostic variables, treatment with medica-
tion, interventional and other therapies, and outcomes.
The writing committee balances completeness with length
of deﬁnition, striving to be as concise as possible to facil-
itate use of these variables. Standardized deﬁnitions for
each variable are a key work product. The writing com-
mittee considers greater speciﬁcity of deﬁnitions against
the information that can be readily and reliably obtained
from a medical record to make these deﬁnitions functional
in various real world settings. Data standards writing
committees aim for clarity, objectivity, and consistency
throughout the writing process.
A main purpose of the writing committee is to construct
deﬁnitions for a topic-speciﬁc area. Once the data element
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tions of those data elements. Sample deﬁnitions from a
variety of existing sources are used to provide assistance to
writing committee members as they draft data element
deﬁnitions.
Whenever possible, data deﬁnitions are linked to
clinical practice guidelines and existing registries.
Existing consensus deﬁnitions, especially those that are
widely adopted or previously published, are not altered
unless there is a compelling reason to change a speciﬁc
deﬁnition, such as a change in evidence or clinical
practice. This consistency across multiple documents and
organizations is critical so as to promote the interoper-
ability of terms and linkages of various databases and
report documents.5.0. Approval and Publication
5.1. PrepublicationProcessesandBoardApproval
These are the review and approval steps taken to prepare
the data standards documents for publication (Appendix 4):
a. Peer Review
Draft sets of data elements are independently
reviewed by ofﬁcial reviewers nominated by the
ACC, AHA, the Task Force, collaborating orga-
nizations, and independent content reviewers,
largely composed of various members from within a
variety of ACC and AHA committees.b. 30-Day Public Comment Period
To provide for broad input and review, the docu-
ment is posted on the Internet for a 30-day public
comment period. Efforts are made to publicize the
comment period to obtain external input from the
widest variety of stakeholders possible for reﬁne-
ment and clariﬁcation of deﬁnitions of data ele-
ments and their interpretation.c. Resolution of Comments Received
After the peer review and public comments are
received, the writing committee chair is respon-
sible for comment resolution and ﬁnalization of
the document, with input from the members of
the writing committee as needed. The writing
committee reviews and approves the ﬁnal docu-
ment after the chair’s completed resolution of the
peer review and public comments. The document
is then reviewed and approved by the entire Task
Force before it is submitted for organizational
approval.d. ACC and AHA Approval
The ﬁnal document is forwarded to the ACC
Board of Trustees and the AHA Scientiﬁc Advisory
and Coordinating Committee for approval before
publication.e. Endorsement
After approval, the ﬁnal document is sent to rele-
vant partnering and collaborating organizations for
approval and endorsement and offered for possible
publication in the respective journals of these
additional organizations.5.2. Publication and Promotion of
Clinical Data Standards
The introduction and deﬁnition sections of the clinical
data standards document are to be published in the Journal
of the American College of Cardiology and Circulation.
Additional information, including revised data standards,
updates, or other supplemental information may be pub-
lished online.
5.3. Updates and Revisions
As with guidelines and performance measures, data stan-
dards require regular review and updates. The writing
committee chair, with the writing committee members and
the Task Force, reviews the clinical data standards docu-
ment 12 to 24 months after publication to assess the extent
to which the document requires updating. Updates may
reﬂect changes in the medical literature or medical practice,
as well as revised ACC/AHA practice guidelines or more
recent efforts in the creation and promotion of data
standards.
6.0. The Future:
Interoperability and Informatics
The development of standardized vocabularies in medicine
facilitates the exchange of clinical information across
numerous domains. A necessary requirement for effective,
unambiguous electronic data interchange is to achieve both
syntactic interoperability (i.e., the standards-based ex-
change of data between computer systems), and semantic
interoperability (i.e., the exchange of data with retention of
the meaning of that data such that machine-computable
logic, data federation, inferential processing, and knowl-
edge discovery are enabled) (7,8). Efforts to develop
consensus vocabularies alone, without the computational
representation and modeling of the meanings, linguistics,
and usage contexts of the terms that make up those vo-
cabularies, are unlikely to accomplish the desired state of
semantic interoperability (9–11).
Informatics is the discipline called on to represent clinical
concepts of a vocabulary via taxonomies (i.e., the relationship
of terms with other terms), as use case diagrams (i.e., ﬂow
charts documenting the context in which a term is used), and
in other technical artifacts needed by the computational
community to achieve semantic interoperability.
Under 2 National Institutes of Health Roadmap con-
tracts (2006–2008), a broad multi-stakeholder public-pri-
vate effort (including the ACC) deﬁned, developed, and
JACC Vol. 63, No. 21, 2014 Hendel et al.
June 3, 2014:2323–34 ACC/AHA Data Standards Methodology
2329tested an approach to harmonize, standardize, represent,
and model clinical data elements (12). The methodology
relies on collaboration between clinical domain experts and
informaticians to (clinically) deﬁne, formalize, and
harmonize data element speciﬁcations while characterizing
with ﬁdelity the clinical concepts via informatics-based
technical models and representation artifacts. As a key
exemplar, the National Institutes of Health Roadmap
project resulted in the creation of a Cardiovascular
Domain Analysis Model (available at http://www.hl7.org/
implement/standards/product_brief.cfm?produc_id¼133)
of the cardiovascular vocabulary terms for EHRs prepared
by the Task Force (13).
The approach delineated in the NIH Roadmap project
should prove formative in deﬁning the future state. For
example, the framework incorporates thesaurus-type re-
lations between broad and speciﬁc concepts, as well as
relations between concepts and representations. This is
highly relevant to the harmonizing of terms both within
the ACC and AHA (e.g., for use in registries) and outside
these organizations (e.g., with SNOMED-CT) because it
is an effective medium for communicating detailed clinical
requirements to information technology experts across
healthcare domains.
The process of Domain Analysis Model development
also explicitly includes the development of stakeholder
consensus through open public comment periods along
with balloting of the Domain Analysis Model as an HL7
informative clinical standard. The technical details
included in the Domain Analysis Model are published as
structured content in publically available vocabulary servers,
speciﬁcally the National Cancer Institute Thesaurus
(http://ncit.nci.nih.gov). This assures that the content can
be consumed by any information technology solution
handling cardiovascular data. It is thus anticipated that the
processes and procedures collaboratively developed via the
National Institutes of Health Roadmap demonstration
project will serve as the basis for the methodology for the
ACC and AHA to write and steward cardiovascular
controlled terminologies for use by the broadest set of
stakeholders of healthcare data.7.0. Conclusions
Since the publication of the original methods paper in
2007, a number of notable changes have occurred
regarding the methodology for the development, speciﬁ-
cation, and maintenance of data standards. First, policies
regarding RWI have undergone signiﬁcant changes and are
now included in this document. Second, the method for
selection of writing committee members has been slightly
altered; that is, the chair and 50% of committee members
are without relevant RWI. Third, and perhaps most
importantly, the need for integration of data standards
across many organizations and disciplines has beenemphasized in this document to strive for harmonization of
data elements. Finally, the Task Force believes that its
members should be the stewards of cardiovascular data
standards and responsible for the creation and maintenance
of these data standards. This stewardship will enable the
use of a common lexicon for a wide variety of applications,
including incorporation into EHRs, elements for struc-
tured reports, the basis for clinical registries and data re-
positories, and facilitation of regulatory submissions.
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Appendix 3. Sample Data Element and Deﬁnition: Myocardial Infarction (6)
Terminology
Concept
(Data Element)
Concept
Deﬁnition
Permissible
Values
Permissible
Values Deﬁnitions
Additional
Notes References
Myocardial infarction,
acute
Clinical syndrome where
there is evidence of
myocardial necrosis in
a clinical setting
consistent with acute
myocardial ischemia
Yes Thygesen K, Alpert JS,
Jaffe AS, et al; the Writing
Group on behalf of the Joint
ESC/ACCF/AHA/WHF Task
Force for the Universal
Deﬁnition of Myocardial
Infarction. Third universal
deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581-98.
Myocardial infarction,
acute
Type of myocardial
infarction
Type 1:
Spontaneous
Spontaneous clinical syndrome
related to atherosclerotic plaque
rupture, ulceration, ﬁssuring,
erosion, or dissection, with
resulting intraluminal thrombus
and leading to decreased
myocardial blood ﬂow or distal
platelet emboli with ensuing
myocyte necrosis. This
classiﬁcation requires a)
detection of a rise and/or fall of
cardiac biomarker values
(preferably cTn) with at least 1
value >99th percentile of the
URL and b) at least 1 of the
following:
– Symptoms of myocardial
ischemia
– New or presumed new signiﬁcant
ST–T changes or new LBBB on the
ECG
– Development of pathological
Q waves on the ECG
– Imaging evidence of new loss of
viable myocardium or new
regional wall motion abnormality
– Identiﬁcation of an
intracoronary thrombus by angi-
ography or autopsy
cTndI or Tdis the preferred
biomarker. If a cTn assay is not
available, the best alternative is
CKMB (measured by mass
assay).
One or more coronary arteries
may be involved.
The patient may have underlying
severe coronary artery disease
but on occasion may have
nonobstructive or no coronary
artery disease.
Type 2: Ischemic
imbalance
Spontaneous clinical syndrome
where a condition other than
coronary artery disease
contributes to an imbalance
between myocardial oxygen
supply and/or demand (e.g.,
coronary endothelial dysfunction,
coronary artery spasm, coronary
embolism, tachy-/
bradyarrhythmias, anemia,
respiratory failure, hypotension,
and hypertension with or without
left ventricular hypertrophy). This
classiﬁcation requires detection
of a) rise and/or fall of cardiac
biomarker values (preferably
cTn) with at least 1 value >99th
percentile of the URL and b) at
least 1 of the following:
– Symptoms of myocardial ischemia
– New or presumed new signiﬁcant
ST–T changes or new LBBB on the
ECG
– Development of pathological Q
waves on the ECG
– Imaging evidence of new loss of
viable myocardium or new
regional wall motion abnormality.
cTndI or Tdis the preferred
biomarker. If a cTn assay is not
available, the best alternative is
CKMB (measured by mass
assay).
Continued on the next page
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Appendix 3. Continued
Terminology
Concept
(Data Element)
Concept
Deﬁnition
Permissible
Values
Permissible
Values Deﬁnitions
Additional
Notes References
Type 3: Death,
no biomarkers
Death where symptoms suggestive
of myocardial ischemia are
present and with (presumed)
new ischemic changes or new
LBBB on ECG but where death
occurs before cardiac biomarkers
can be obtained or before
cardiac biomarker values could
rise.
Type 4a: PCI
related
Myocardial infarction associated
with and occurring within 48 h of
PCI, with elevation of cardiac
biomarker values to >5 99th
percentile of the URL in patients
with normal baseline values
(99th percentile URL) or a rise
of cardiac biomarker
values 20% if the baseline
values are elevated and are
stable or falling. This
classiﬁcation also requires at
least 1 of the following:
– Symptoms of myocardial
ischemia
– New ischemic ECG changes or
new LBBB
– Angiographic loss of patency of a
major coronary artery or a side
branch or persistent slow- or
no-ﬂow or embolization
– Imaging evidence of new loss of
viable myocardium or new
regional wall motion abnormality.
cTndI or Tdis the preferred
biomarker. If a cTn assay is not
available, the best alternative is
CKMB (measured by mass
assay).
Type 4b: Stent
thrombosis
Myocardial infarction associated
with stent thrombosis as
detected by coronary
angiography or at autopsy, where
symptoms suggestive of
myocardial ischemia are present,
and with a rise and/or fall of
cardiac biomarkers values, with
at least 1 value >99th percentile
of the URL.
cTndI or Tdis the preferred
biomarker. If a cTn assay is not
available, the best alternative is
CKMB (measured by mass
assay).
Type 4c: Stent
restenosis
Myocardial infarction associated
with stent restenosis as detected
by coronary angiography or at
autopsy, occurring >48 h after
PCI, without evidence of stent
thrombosis but with symptoms
suggestive of myocardial
ischemia, and with elevation of
cardiac biomarker values to
>99th percentile of the URL. This
classiﬁcation also requires the
following:
– Does not meet criteria for any
other classiﬁcation of myocardial
infarction
– Presence of 50% stenosis at the
site of previous successful stent
PCI.
cTndI or Tdis the preferred
biomarker. If a cTn assay is not
available, the best alternative is
CKMB (measured by mass
assay).
Type 4c is described in the Third
Universal Deﬁnition of MI.
Continued on the next page
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Appendix 3. Continued
Terminology
Concept
(Data Element)
Concept
Deﬁnition
Permissible
Values
Permissible
Values Deﬁnitions
Additional
Notes References
Type 5: CABG
related
Myocardial infarction associated
with and occurring within 48 h of
CABG surgery, with elevation of
cardiac biomarker values to
>10 99th percentile of the URL
in patients with normal baseline
cardiac biomarker values (99th
percentile URL). This
classiﬁcation also requires at
least 1 of the following:
– New pathologic Q waves or new
LBBB on ECG
– Angiographic new graft or new
native coronary artery occlusion
– Imaging evidence of new loss of
viable myocardium or new
regional wall motion abnormality.
cTndI or Tdis the preferred
biomarker. If a cTn assay is not
available, the best alternative is
CKMB (measured by mass
assay).
ACC indicates American College of Cardiology; AHA, American Heart Association; CABG, coronary artery bypass graft; CKMB, creatine kinase MB; cTn, cardiac troponin; ECG, electrocardiogram;
ESC, European Society of Cardiology; LBBB, left bundle-branch block; PCI, percutaneous coronary intervention; ST–T, ST-segment–T wave; URL, upper reference limit; and WHF, World Heart
Federation.
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